CR9181A - Antiangiogenesis terapia de autoinmunidad de enfermedad en pacientes a quienes a fallado la terapia previa - Google Patents
Antiangiogenesis terapia de autoinmunidad de enfermedad en pacientes a quienes a fallado la terapia previaInfo
- Publication number
- CR9181A CR9181A CR9181A CR9181A CR9181A CR 9181 A CR9181 A CR 9181A CR 9181 A CR9181 A CR 9181A CR 9181 A CR9181 A CR 9181A CR 9181 A CR9181 A CR 9181A
- Authority
- CR
- Costa Rica
- Prior art keywords
- therapy
- failed
- antiangiogenesis
- patients
- self
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente solicitud describe la terapia con antagonistas de angiogenesis tales como anticuerpos antiVEGF. En particular, la solicitud describe el uso de tales antagonistas para tratar la enfermedad autoinmune en un paciente en quien ha fallado el tratamiento anterior tal como el tratamiento con DMARDs o inhibidores-TNFx.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63716904P | 2004-12-17 | 2004-12-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR9181A true CR9181A (es) | 2008-07-31 |
Family
ID=36177836
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR9181A CR9181A (es) | 2004-12-17 | 2007-06-13 | Antiangiogenesis terapia de autoinmunidad de enfermedad en pacientes a quienes a fallado la terapia previa |
Country Status (23)
Country | Link |
---|---|
US (2) | US20060134111A1 (es) |
EP (1) | EP1824885A1 (es) |
JP (1) | JP2008524241A (es) |
KR (1) | KR20070086218A (es) |
CN (1) | CN101120020A (es) |
AR (1) | AR052056A1 (es) |
AU (1) | AU2005316403A1 (es) |
BR (1) | BRPI0518105A (es) |
CA (1) | CA2587932A1 (es) |
CR (1) | CR9181A (es) |
IL (1) | IL183347A0 (es) |
MA (1) | MA29366B1 (es) |
MX (1) | MX2007007165A (es) |
NO (1) | NO20073651L (es) |
NZ (1) | NZ555286A (es) |
PE (1) | PE20061075A1 (es) |
RU (1) | RU2007126970A (es) |
SG (1) | SG158089A1 (es) |
SV (1) | SV2006002342A (es) |
TN (1) | TNSN07191A1 (es) |
TW (1) | TW200634026A (es) |
WO (1) | WO2006066086A1 (es) |
ZA (1) | ZA200704898B (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7820161B1 (en) * | 1999-05-07 | 2010-10-26 | Biogen Idec, Inc. | Treatment of autoimmune diseases |
MXPA03002262A (es) * | 2000-09-18 | 2003-10-15 | Idec Pharma Corp | Terapia de combinacion para tratamiento de enfermedades autoinmunes usando una combinacion de anticuerpos inmunorreguladores/supresores de celulas b. |
SG10201504094SA (en) * | 2003-11-05 | 2015-06-29 | Roche Glycart Ag | Cd20 antibodies with increased fc receptor binding affinity and effector function |
ATE470454T1 (de) * | 2004-09-13 | 2010-06-15 | Genzyme Corp | Multimere konstrukte |
GB0612721D0 (en) | 2006-06-27 | 2006-08-09 | Novartis Ag | Organic compounds |
WO2008031835A2 (en) * | 2006-09-13 | 2008-03-20 | Novartis Ag | Method of treating autoimmune diseases using vegf-pathway inhibitors |
TWI468417B (zh) | 2007-11-30 | 2015-01-11 | Genentech Inc | 抗-vegf抗體 |
AR073295A1 (es) | 2008-09-16 | 2010-10-28 | Genentech Inc | Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion. |
EP2727996A1 (en) | 2008-11-06 | 2014-05-07 | The Johns-Hopkins University | Treatment of chronic inflammatory respiratory disorders with NP1 inhibitors |
MX356367B (es) * | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
JP5680547B2 (ja) * | 2008-12-23 | 2015-03-04 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | 抗血管形成活性を有するインヒビターのためのバイオマーカー |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
RU2573994C2 (ru) | 2010-02-10 | 2016-01-27 | Иммьюноджен, Инк | Антитела против cd20 и их применение |
PT2601214T (pt) | 2010-08-06 | 2017-12-20 | Genzyme Corp | Composições de antagonistas de vegf e utilizações destes |
US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
MX2016012779A (es) * | 2014-03-31 | 2017-04-27 | Genentech Inc | Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40. |
ES2622983T3 (es) * | 2015-02-11 | 2017-07-10 | Deutsches Krebsforschungszentrum | Terapia contra el cáncer con un parvovirus combinado con bevacizumab |
WO2019173692A2 (en) | 2018-03-09 | 2019-09-12 | Agenus Inc. | Anti-cd73 antibodies and methods of use thereof |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL47062A (en) * | 1975-04-10 | 1979-07-25 | Yeda Res & Dev | Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde |
US4665077A (en) * | 1979-03-19 | 1987-05-12 | The Upjohn Company | Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4676980A (en) * | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
IL85746A (en) * | 1988-03-15 | 1994-05-30 | Yeda Res & Dev | Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IE922437A1 (en) * | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US5739277A (en) * | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
US6884879B1 (en) * | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
US6416758B1 (en) * | 1999-04-28 | 2002-07-09 | Board Of Regents, The University Of Texax System | Antibody conjugate kits for selectively inhibiting VEGF |
US20040120950A1 (en) * | 2002-12-20 | 2004-06-24 | Kari Alitalo | Modulation of VEGF-C/VEGFR-3 interactions in the treatment of rheumatoid arthritis |
US20050106667A1 (en) * | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
-
2005
- 2005-12-16 JP JP2007546933A patent/JP2008524241A/ja not_active Withdrawn
- 2005-12-16 CN CNA2005800481049A patent/CN101120020A/zh active Pending
- 2005-12-16 PE PE2005001499A patent/PE20061075A1/es not_active Application Discontinuation
- 2005-12-16 SV SV2005002342A patent/SV2006002342A/es unknown
- 2005-12-16 NZ NZ555286A patent/NZ555286A/en not_active IP Right Cessation
- 2005-12-16 MX MX2007007165A patent/MX2007007165A/es not_active Application Discontinuation
- 2005-12-16 EP EP05854343A patent/EP1824885A1/en not_active Withdrawn
- 2005-12-16 AU AU2005316403A patent/AU2005316403A1/en not_active Abandoned
- 2005-12-16 RU RU2007126970/15A patent/RU2007126970A/ru not_active Application Discontinuation
- 2005-12-16 SG SG200907898-1A patent/SG158089A1/en unknown
- 2005-12-16 ZA ZA200704898A patent/ZA200704898B/xx unknown
- 2005-12-16 TW TW094144950A patent/TW200634026A/zh unknown
- 2005-12-16 CA CA002587932A patent/CA2587932A1/en not_active Abandoned
- 2005-12-16 AR ARP050105315A patent/AR052056A1/es not_active Application Discontinuation
- 2005-12-16 WO PCT/US2005/045600 patent/WO2006066086A1/en active Application Filing
- 2005-12-16 BR BRPI0518105-4A patent/BRPI0518105A/pt not_active IP Right Cessation
- 2005-12-16 US US11/303,811 patent/US20060134111A1/en not_active Abandoned
- 2005-12-16 KR KR1020077013483A patent/KR20070086218A/ko not_active Application Discontinuation
-
2007
- 2007-05-18 TN TNP2007000191A patent/TNSN07191A1/fr unknown
- 2007-05-21 IL IL183347A patent/IL183347A0/en unknown
- 2007-06-13 CR CR9181A patent/CR9181A/es not_active Application Discontinuation
- 2007-07-12 MA MA30069A patent/MA29366B1/fr unknown
- 2007-07-16 NO NO20073651A patent/NO20073651L/no not_active Application Discontinuation
-
2008
- 2008-02-19 US US12/033,557 patent/US20080214789A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
PE20061075A1 (es) | 2006-11-15 |
CA2587932A1 (en) | 2006-06-22 |
RU2007126970A (ru) | 2009-01-27 |
NZ555286A (en) | 2010-04-30 |
SV2006002342A (es) | 2006-06-01 |
TNSN07191A1 (en) | 2008-11-21 |
ZA200704898B (en) | 2009-03-25 |
NO20073651L (no) | 2007-09-10 |
CN101120020A (zh) | 2008-02-06 |
US20060134111A1 (en) | 2006-06-22 |
US20080214789A1 (en) | 2008-09-04 |
IL183347A0 (en) | 2007-09-20 |
TW200634026A (en) | 2006-10-01 |
AR052056A1 (es) | 2007-02-28 |
BRPI0518105A (pt) | 2008-11-04 |
JP2008524241A (ja) | 2008-07-10 |
KR20070086218A (ko) | 2007-08-27 |
MX2007007165A (es) | 2007-08-14 |
WO2006066086A1 (en) | 2006-06-22 |
AU2005316403A1 (en) | 2006-06-22 |
SG158089A1 (en) | 2010-01-29 |
EP1824885A1 (en) | 2007-08-29 |
MA29366B1 (fr) | 2008-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR9181A (es) | Antiangiogenesis terapia de autoinmunidad de enfermedad en pacientes a quienes a fallado la terapia previa | |
AR059390A1 (es) | Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopausicos | |
AR077896A1 (es) | Terapia de baja frecuencia con acetato de glatiramer. uso. acetato de glatiramer. | |
EA200802204A1 (ru) | Применение ингибиторов dpp iv | |
AR083878A1 (es) | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento | |
NZ603319A (en) | Diabetes therapy | |
AR077573A2 (es) | Uso de un inhibidor de tnf y composicion farmaceutica que lo comprende | |
TW200640488A (en) | Extending time to disease progression or survival in cancer patients | |
AR062522A1 (es) | Tratamiento de desordenes en cartilagos | |
PA8637201A1 (es) | Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa | |
WO2007136518A3 (en) | Treatment of autoimmune disorders | |
BR112014018485A8 (pt) | Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf | |
BR112013029256A2 (pt) | "combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina". | |
PL1680128T3 (pl) | Heksafosforan mio-inozytolu do stosowania miejscowego | |
WO2010093993A3 (en) | Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance | |
BRPI0418157A (pt) | terapêutica de tumores alogênicos | |
EA200970345A1 (ru) | Лечение гипербилирубинемии новорожденных с использованием низких дозировок станнсопорфина | |
CA2904533C (en) | Enhanced osteogenic activity of daidzein analogs on human mesenchymal stem cells | |
ECSP077843A (es) | Tratamiento o prevención del prurito | |
AR079000A1 (es) | Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas | |
AR081925A1 (es) | Uso de ranolazina para el tratamiento de la hipertension pulmonar | |
DK1732551T3 (da) | Perhexilin til behandling af kronisk hjertesvigt | |
CR8584A (es) | Piperazinas derivadas de urea para el tratamiento de la endometrosis | |
ATE495750T1 (de) | Sulfatide zur behandlung von autoimmunkrankheiten | |
ECSP034632A (es) | Uso de compuestos del 6-dimetilaminometil-1-fenil-ciclohexaco sustituido en la terapia de la incontinencia urinaria |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |